ESR1 and breast carcinoma: Although early detection and chemotherapeutic treatments have contributed to recent modest declines in breast cancer mortality, the incidence of estrogen receptor negative (ER-) breast cancer has not changed significantly in over 30 years and ~40,000 women succumb to breast cancer each year [1].